Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 43Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

camrelizumab 2spartalizumab 1pembrolizumab 1lenvatinib 1apatinib 1S 1 (combination) 1Neoadjuvant Therapy 1Hyperthermic Intraperitoneal Chemotherapy 1Docetaxel 1Albumin-Bound Paclitaxel 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Gastric Adenocarcinoma × apatinib × Clear all
NCT04174339 2019-11-22

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Fujian Cancer Hospital

Phase NA Unknown
20 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡